Apar Kishor Ganti - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Apar Kishor Ganti's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Apar Kishor Ganti
Verified
Associate Editor, Journal of Oncology Practice
Omaha
Beats
Africa, public health science, international development global health, South Africa medicine, global healthhealth
I don't cover anything without a connection to government and people.
Content
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials
By Robin R. High, Apar Kishor Ganti, Alissa Marr, Clayton K. Oakley, Amulya Yellala, Sunil Tulpule| ONCOLOGY journal Verified December 5, 2024By OncologyONCOLOGY Vol 38, Issue 12Pages: 462-468These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens. AbstractIntroduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria.
By Apar Kishor Ganti| MDEdge Verified Slideshow below. In the United States and among veterans, lung cancer has the highest rate of cancer-related mortality.
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials
By Robin R. High, Apar Kishor Ganti, Alissa Marr, Clayton K. Oakley, Amulya Yellala, Sunil Tulpule| ONCOLOGY journal Verified December 5, 2024By OncologyONCOLOGY Vol 38, Issue 12Pages: 462-468These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens. AbstractIntroduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria.
Company Info
Journal of Oncology Practice
Omaha, United States